Nadja Jaekel
About
Nadja Jaekel is a scholar working on Hematology, Genetics and Molecular Biology.
According to data from OpenAlex, Nadja Jaekel has authored 22 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 10 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Nadja Jaekel's work include Acute Myeloid Leukemia Research (11 papers), Hemoglobinopathies and Related Disorders (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Nadja Jaekel is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Hemoglobinopathies and Related Disorders (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Nadja Jaekel collaborates with scholars based in Germany, Austria and Switzerland. Nadja Jaekel's co-authors include Haifa Kathrin Al‐Ali, Dietger Niederwieser, Claudia Wickenhauser, Rainer Krahl, Georg Maschmeyer, Christian Junghanß, Michael Cross, Gerhard Behre, Thoralf Lange and Monika Brüggemann and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.
In The Last Decade
Nadja Jaekel
19 papers receiving 360 citations
Peers
Nadja Jaekel
Barbara Rocca Italy
Laurence Baranger France
Marilena Caresana Italy
Patrizia Scaravaglio Italy
Paola Maria Cavigliano Italy
V. Parlier Switzerland
D. Snyder United States
Thamer Sliwa Austria
Chang‐Liang Lai Taiwan
Sherry Pierce United States
Citations per year, relative to Nadja Jaekel Nadja Jaekel (= 1×)
peers
Barbara Rocca
Countries citing papers authored by Nadja Jaekel
Since
Specialization
Citations
This map shows the geographic impact of Nadja Jaekel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadja Jaekel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadja Jaekel more than expected).
Fields of papers citing papers by Nadja Jaekel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nadja Jaekel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadja Jaekel. The network helps show where Nadja Jaekel may publish in the future.
Co-authorship network of co-authors of Nadja Jaekel
This figure shows the co-authorship network connecting the top 25 collaborators of Nadja Jaekel. A scholar is included among the top collaborators of Nadja Jaekel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadja Jaekel. Nadja Jaekel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kegel, Thomas, Christine Dierks, Pablo Villavicencio‐Lorini, et al.. (2025). Case Report: Influence of BRCA1 germline mutation on treatment-related morbidity of a non-seminomatous germ cell tumor patient. Frontiers in Oncology. 15. 1579574–1579574.
2.
Bauer, Marcus, Hubert Hackl, Nadja Jaekel, et al.. (2024). Association of immune evasion in myeloid sarcomas with disease manifestation and patients’ survival. Frontiers in Immunology. 15. 1396187–1396187.
3.
Engelmann, Robby, Nadja Jaekel, Frank Bernhard Kraus, et al.. (2023). Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia. Blood Advances. 7(14). 3403–3415.
4.
Jaekel, Nadja, Robby Engelmann, Frank Bernhard Kraus, et al.. (2022). Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). Cancers. 14(6). 1544–1544.
5.
Bauer, Marcus, Christoforos Vaxevanis, Haifa Kathrin Al‐Ali, et al.. (2021). Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia. Cancers. 13(2). 186–186.
6.
Bauer, Marcus, Christoforos Vaxevanis, Haifa Kathrin Al‐Ali, et al.. (2020). Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins. International Journal of Molecular Sciences. 21(19). 7140–7140.
7.
Jaekel, Nadja, et al.. (2020). A Rare Hemoglobinopathy as a Cause of Erythrocytosis in a Patient with Suspected JAK2V617F Negative Polycythemia Vera: A Case Report. 14(2).
8.
Jaekel, Nadja, et al.. (2019). Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F‐ and MPLW515 L‐positive myelofibrosis. Genes Chromosomes and Cancer. 58(11). 747–755.
9.
Jaekel, Nadja, Stefan Albrecht, Gesine Bug, et al.. (2015). Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 51(1). 89–95.
10.
Al‐Ali, Haifa Kathrin, Nadja Jaekel, Rainer Krahl, et al.. (2015). Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): First Data of the Interim Analysis of the DRKS00004519 Study of the East German Study Group (OSHO). Blood. 126(23). 1346–1346.
11.
Al‐Ali, Haifa Kathrin, et al.. (2014). Response-Adapted Sequential Azacitidine and Induction Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML Eligible for Chemotherapy (RAS-AZIC): Results of the Phase I of the DRKS00004519 Study. Blood. 124(21). 2310–2310.
12.
Al‐Ali, Haifa Kathrin, Nadja Jaekel, & Dietger Niederwieser. (2013). The role of hypomethylating agents in the treatment of elderly patients with AML. Journal of Geriatric Oncology. 5(1). 89–105.
13.
Al‐Ali, Haifa Kathrin, Michael Cross, Enrica Bach, et al.. (2013). Pretreatment long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia. OncoTargets and Therapy. 6. 741–741.
14.
Jaekel, Nadja, Gerhard Behre, Claudia Wickenhauser, et al.. (2013). Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplantation. 49(2). 179–184.
15.
Gisslinger, Heinz, Mary Frances McMullin, Nadja Jaekel, et al.. (2012). A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to <100 x 109/l.. Journal of Clinical Oncology. 30(15_suppl). TPS6642–TPS6642.
16.
Eisfeld, Ann‐Kathrin, Rainer Krahl, Nadja Jaekel, Dietger Niederwieser, & Haifa Kathrin Al‐Ali. (2012). Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.. PubMed. 2(4). 243–53.
17.
Al‐Ali, Haifa Kathrin, Nadja Jaekel, Christian Junghanß, et al.. (2011). Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leukemia & lymphoma. 53(1). 110–117.
18.
Al‐Ali, Haifa Kathrin, Nadja Jaekel, Gesine Bug, et al.. (2010). The Oral Iron Chelator Deferasirox for Treatment of Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation Does Not Appear to Interfere with the Calcineurin Inhibitor Cyclosporin Trough Serum Levels. Blood. 116(21). 1826–1826.
19.
Cross, Michael, Nadja Jaekel, Rainer Krahl, et al.. (2009). Low Levels of Global (LINE) and CDH13 Methylation at Diagnosis and Rapid Clearance of Marrow Blasts Correlate with A Better Haematological Response to Azacitidine in Patients with Newly Diagnosed and Refractory/Relapsed AML Not Eligible for or Resistant to Chemotherapy: A Multi-Centre Phase I/II-Study of the East German Haematology and Oncology Study Group (OSHO).. Blood. 114(22). 2642–2642.
20.
Heyn, Simone, Nadja Jaekel, Robert Rohrberg, et al.. (2007). Bortezomib in Combination with Bendamustine and Prednisone in the Treatment of Patients with Refractory/Relapsed Multiple Myeloma.. Blood. 110(11). 2723–2723.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Barbara Rocca Breakdown of academic impact, for papers by Laurence Baranger Breakdown of academic impact, for papers by Marilena Caresana Breakdown of academic impact, for papers by Patrizia Scaravaglio Breakdown of academic impact, for papers by Paola Maria Cavigliano Breakdown of academic impact, for papers by V. Parlier Breakdown of academic impact, for papers by D. Snyder Breakdown of academic impact, for papers by Thamer Sliwa Breakdown of academic impact, for papers by Chang‐Liang Lai Breakdown of academic impact, for papers by Sherry Pierce